4-Aminopyridine is a promising treatment option for patients with gain-of-function KCNA2 -encephalopathy
The DOI matches its Crossref record; 68 of the 69 references it cites were found in a registry or an index.
Abstract
4-Aminopyridine is a potential therapeutic option for a subgroup of patients with KCNA2 -encephalopathy and gain-of-function variants.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Early Identification of Refractory Epilepsy
Kwan, P., & Brodie, M. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002033420503 · Cited by 5,204 · cited 1×
“Previous studies of patients with common epilepsies of different etiologies have shown that patients treated with the first ASM achieve seizure freedom in about 50% of cases, with the second ASM only in 10-15% of cases, whereas with the third or even more regimens of ASM only a few percent of the initial cohort reach…”
BackgroundScheffer, I. E., Berkovic, S., Capovilla, G., Connolly, M. B., French, J., Guilhoto, L., Hirsch, E., Jain, S., Mathern, G. W., Moshé, S. L., et al. (2017) · Epilepsia · doi:10.1111/epi.13709 · Cited by 5,054
Fisher, R. S., Cross, J. H., French, J. A., Higurashi, N., Hirsch, E., Jansen, F. E., Lagae, L., Moshé, S. L., Peltola, J., Roulet Perez, E., et al. (2017) · Epilepsia · doi:10.1111/epi.13670 · Cited by 3,483
Wilson, I. B. (1995) · JAMA · doi:10.1001/jama.1995.03520250075037 · Cited by 3,027
Chen, Z., Brodie, M. J., Liew, D., & Kwan, P. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.3949 · Cited by 1,514
Gutman, G. A., Chandy, K. G., Grissmer, S., Lazdunski, M., Mckinnon, D., Pardo, L. A., Robertson, G. A., Rudy, B., Sanguinetti, M. C., Stühmer, W., et al. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.4.10 · Cited by 887
Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
Kim, J., Hu, C., Moufawad El Achkar, C., Black, L. E., Douville, J., Larson, A., Pendergast, M. K., Goldkind, S. F., Lee, E. A., Kuniholm, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813279 · Cited by 827
The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?
Lillie, E. O., Patay, B., Diamant, J., Issell, B., Topol, E. J., & Schork, N. J. (2011) · Personalized Medicine · doi:10.2217/pme.11.7 · Cited by 706 · cited 1×
“N-of-1 trials are a possibility to test a medication that is licensed for another indication in a single patient for which a rationale exists that this drug could have beneficial effects (24-27).”
BackgroundDetermining Optimal Therapy — Randomized Trials in Individual Patients
Guyatt, G., Sackett, D., Taylor, D. W., Ghong, J., Roberts, R., & Pugsley, S. (1986) · New England Journal of Medicine · doi:10.1056/nejm198604033141406 · Cited by 579
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis
Goodman, A. D., Brown, T. R., Edwards, K. R., Krupp, L. B., Schapiro, R. T., Cohen, R., Marinucci, L. N., Blight, A. R., & on behalf of the MSF204 Investigators (2010) · Annals of Neurology · doi:10.1002/ana.22240 · Cited by 374 · cited 1×
“Furthermore, it is a drug licensed for gait disturbance in adults with multiple sclerosis, with a well-established safety profile (21-23).”
Veh, R. W., Lichtinghagen, R., Sewing, S., Wunder, F., Grumbach, I. M., & Pongs, O. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb00641.x · Cited by 328
Quantifying the response to antiepileptic drugs: Effect of past treatment history
Schiller, Y., & Najjar, Y. (2008) · Neurology · doi:10.1212/01.wnl.0000286959.22040.6e · Cited by 313
Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres
Sherratt, R. M., Bostock, H., & Sears, T. A. (1980) · Nature · doi:10.1038/283570a0 · Cited by 303 · cited 2×
“4-aminopyridine (4-AP) is a known blocker of KV1 and some other KV channels (13-15).”
BackgroundSOX5 Controls the Sequential Generation of Distinct Corticofugal Neuron Subtypes
Lai, T., Jabaudon, D., Molyneaux, B. J., Azim, E., Arlotta, P., Menezes, J. R. L., & Macklis, J. D. (2008) · Neuron · doi:10.1016/j.neuron.2007.12.023 · Cited by 300
De novo loss- or gain-of-function mutations in KCNA2 cause epileptic encephalopathy
EuroEPINOMICS, R. E. S., Syrbe, S., Hedrich, U. B. S., Riesch, E., Djémié, T., Müller, S., Møller, R. S., Maher, B., Hernandez-Hernandez, L., Synofzik, M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3239 · Cited by 276
Self-citationA randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias
Strupp, M., Kalla, R., Claassen, J., Adrion, C., Mansmann, U., Klopstock, T., Freilinger, T., Neugebauer, H., Spiegel, R., Dichgans, M., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318225ab07 · Cited by 210 · cited 1×
“4AP has been shown to be effective in small but well-designed clinical controlled trials in patients with downbeat nystagmus and episodic ataxia type 2 (16-18), as well as in some other patients with ataxia (19, 20).”
BackgroundA roadmap for precision medicine in the epilepsies
(2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00199-4 · Cited by 204
Voltage‐gated potassium channels: from hyperexcitability to excitement
Pongs, O. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00535-9 · Cited by 192
Unexplained early onset epileptic encephalopathy: Exome screening and phenotype expansion
Allen, N. M., Conroy, J., Shahwan, A., Lynch, B., Correa, R. G., Pena, S. D. J., McCreary, D., Magalhães, T. R., Ennis, S., Lynch, S. A., et al. (2016) · Epilepsia · doi:10.1111/epi.13250 · Cited by 180
Self-citationMasking epilepsy by combining two epilepsy genes
Glasscock, E., Qian, J., Yoo, J. W., & Noebels, J. L. (2007) · Nature Neuroscience · doi:10.1038/nn1999 · Cited by 174 · cited 1×
“In addition, the observed beneficial effects of 4-AP might be attributed to an increase in presynaptic Ca2+ influx, which could explain short-term seizure cessation after administration of 4-AP in an absence epilepsy mouse model caused by mutant P/Q-type Ca2+ channels with decreased network excitability (54).”
BackgroundHedrich, U. B. S., Liautard, C., Kirschenbaum, D., Pofahl, M., Lavigne, J., Liu, Y., Theiss, S., Slotta, J., Escayg, A., Dihné, M., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.0721-14.2014 · Cited by 164
Self-citationClinical spectrum and genotype–phenotype associations of KCNA2-related encephalopathies
Masnada, S., Hedrich, U. B. S., Gardella, E., Schubert, J., Kaiwar, C., Klee, E. W., Lanpher, B. C., Gavrilova, R. H., Synofzik, M., Bast, T., et al. (2017) · Brain · doi:10.1093/brain/awx184 · Cited by 164
Self-citationOttenbacher, K. J., Msall, M. E., Lyon, N. R., Duffy, L. C., Granger, C. V., & Braun, S. (1997) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/s0003-9993(97)90302-6 · Cited by 160
Standardized computer-based organized reporting of EEG: SCORE – Second version
Beniczky, S., Aurlien, H., Brøgger, J. C., Hirsch, L. J., Schomer, D. L., Trinka, E., Pressler, R., Wennberg, R. A., Visser, G. H., Eisermann, M., et al. (2017) · Clinical Neurophysiology · doi:10.1016/j.clinph.2017.07.418 · Cited by 159
Self-citationThe effects of 4‐aminopyridine in multiple sclerosis patients
Bever, C. T., Young, D., Anderson, P. A., Krumholz, A., Conway, K. L., Leslie, J. L., Eddington, N. D., Plaisance, K. I., PANITCH, H. S., Dhib-Jalbut, S. S., et al. (1994) · Neurology · doi:10.1212/wnl.44.6.1054 · Cited by 156
Goodman, A. D., Cohen, J. A., Cross, A. H., Vollmer, T. L., Rizzo, M., Cohen, R., Marinucci, L. N., & Blight, A. R. (2007) · Multiple Sclerosis Journal · doi:10.1177/1352458506069538 · Cited by 156
Ottenbacher, K. J., Taylor, E. T., Msall, M. E., Braun, S., Lane, S. J., Granger, C. V., Lyons, N., & Duffy, L. C. (1996) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.1996.tb15047.x · Cited by 153
Health care concerns and guidelines for adults with Down syndrome
Allen, M. I. V., Fung, J., & Jurenka, S. B. (1999) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19990625)89:2<62::aid-ajmg3>3.0.co;2-t · Cited by 153
The WeeFIM instrument: its utility in detecting change in children with developmental disabilities.
Ottenbacher, K., Msall, M., Lyon, N., Duffy, L. C., Ziviani, J., Granger, C., Braun, S., & Feidler, R. C. (2000) · Archives of Physical Medicine and Rehabilitation · doi:10.1053/apmr.2000.9387 · Cited by 140
van Diemen, H. A. M., Polman, C. H., van Dongen, T. M. M. M., Loenen, A. C. V., Nauta, J. J. P., Taphoorn, M. J. B., van Walbeek, H. K., & Koetsier, J. C. (1992) · Annals of Neurology · doi:10.1002/ana.410320203 · Cited by 137
4-Aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus
Kalla, R., Glasauer, S., Büttner, U., Brandt, T., & Strupp, M. (2007) · Brain · doi:10.1093/brain/awm172 · Cited by 136
Monaghan, M. M., Trimmer, J. S., & Rhodes, K. J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-16-05973.2001 · Cited by 132
Treatment with oral 4‐aminopyridine in disorders of neuromuscular transmission
Murray, N. M. F., & Newsom–Davis, J. (1981) · Neurology · doi:10.1212/wnl.31.3.265 · Cited by 124
Standardized Computer‐based Organized Reporting of EEG: SCORE
Beniczky, S., Aurlien, H., Brøgger, J. C., Fuglsang‐Frederiksen, A., Martins‐da‐Silva, A., Trinka, E., Visser, G., Rubboli, G., Hjalgrim, H., Stefan, H., et al. (2013) · Epilepsia · doi:10.1111/epi.12135 · Cited by 123
Self-citation4-Aminopyridine in the Treatment of Patients With Multiple Sclerosis: Long-term Efficacy and Safety
Polman, C. H. (1994) · Archives of Neurology · doi:10.1001/archneur.1994.00540150090022 · Cited by 122
4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review
Jensen, H. B., Ravnborg, M., Dalgas, U., & Stenager, E. (2014) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285613512712 · Cited by 116
Dominant KCNA2 mutation causes episodic ataxia and pharmacoresponsive epilepsy
Corbett, M. A., Bellows, S. T., Li, M., Carroll, R., Micallef, S., Carvill, G. L., Myers, C. T., Howell, K. B., Maljevic, S., Lerche, H., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003309 · Cited by 101
Self-citationFunctional Independence Measure (WeeFIM) for Chinese Children: Hong Kong Cohort
Wong, V. C. N., Wong, S. S.-N., Chan, K., & Wong, W. H. S. (2002) · PEDIATRICS · doi:10.1542/peds.109.2.e36 · Cited by 98
Aminopyridines for the treatment of neurologic disorders
Strupp, M. L., Teufel, J., Zwergal, A., Schniepp, R., Khodakhah, K., & Feil, K. (2017) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000000321 · Cited by 94 · cited 1×
“2-specific effects could play a role for the clinical improvement (53).”
BackgroundAminopyridines for symptomatic treatment in multiple sclerosis
Solari, A., Uitdehaag, B. M. J., Giuliani, G., Pucci, E., & Taus, C. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001330 · Cited by 78
Sperle, P. A., Ottenbacher, K. J., Braun, S., Lane, S. J., & Nochajski, S. M. (1997) · American Journal of Occupational Therapy · doi:10.5014/ajot.51.1.35 · Cited by 77
Pena, S. D. J., & Coimbra, R. L. M. (2015) · Clinical Genetics · doi:10.1111/cge.12542 · Cited by 76
Shieh, C. C., & Kirsch, G. E. (1994) · Biophysical Journal · doi:10.1016/s0006-3495(94)80718-0 · Cited by 72 · cited 1×
“(Leu328Val) mutant channels could be explained by the localization of Leu328 near the 4-AP binding site (37).”
BackgroundLemeignan, M., Millart, H. G., Lamiable, D., Molgó, J., & Lechat, P. (1984) · Brain Research · doi:10.1016/0006-8993(84)90875-8 · Cited by 70
Long, Q., Wang, H., Gao, W., Fan, Y., Li, Y., Ma, Y., Yang, Y., Shi, H., Chen, B., Meng, H., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005965 · Cited by 62
The Use of Aminopyridines in Neurological Disorders
Sedehizadeh, S., Keogh, M. J., & Maddison, P. (2012) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31825a68c5 · Cited by 59 · cited 1×
“Furthermore, it is a drug licensed for gait disturbance in adults with multiple sclerosis, with a well-established safety profile (21-23).”
BackgroundSite of action and active form of aminopyridines in squid axon membranes.
Kirsch, G. E., & Narahashi, T. (1983) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21412-4 · Cited by 58 · cited 2×
“4-aminopyridine (4-AP) is a known blocker of KV1 and some other KV channels (13-15).”
Background4-Aminopyridine Toxicity: a Case Report and Review of the Literature
King, A. M., Menke, N. B., Katz, K. D., & Pizon, A. F. (2012) · Journal of Medical Toxicology · doi:10.1007/s13181-012-0248-9 · Cited by 53
Fampridine and Acetazolamide in EA2 and Related Familial EA
Muth, C., Teufel, J., Schöls, L. J., Synofzik, M., Franke, C., Timmann, D., Mansmann, U., & Strupp, M. (2020) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000001017 · Cited by 53
Self-citationAllou, L., Julia, S., Amsallem, D., El Chehadeh, S., Lambert, L., Thevenon, J., Duffourd, Y., Saunier, A., Bouquet, P., Pere, S., et al. (2017) · Clinical Genetics · doi:10.1111/cge.12784 · Cited by 52
Use of Functional Assessment in Children with Developmental Disabilities
Msall, M. E., DiGaudio, K. M., & Duffy, L. C. (1993) · Physical Medicine and Rehabilitation Clinics of North America · doi:10.1016/s1047-9651(18)30567-9 · Cited by 52
Aminopyridines and Acetyl-DL-leucine: New Therapies in Cerebellar Disorders
Kalla, R., & Strupp, M. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180905093535 · Cited by 51
Trenité, D. G. A. K.-N., Smit, A., Velis, D. N., Willemse, J., & Boas, W. V. E. (1990) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.1990.tb08465.x · Cited by 50
Making the switch: From case studies to N-of-1 trials
Margolis, A. R., & Giuliano, C. A. (2019) · Epilepsy & Behavior Reports · doi:10.1016/j.ebr.2019.100336 · Cited by 50
Block by 4‐aminopyridine of a Kv1.2 delayed rectifier K+ current expressed in Xenopus oocytes.
Russell, S. N., Publicover, N. G., Hart, P. J., Carl, A., Hume, J. R., Sanders, K. M., & Horowitz, B. (1994) · The Journal of Physiology · doi:10.1113/jphysiol.1994.sp020464 · Cited by 44
Sridhar, A., da Cunha, D. N. Q., Lacombe, V. A., Zhou, Q., Fox, J. J., Hamlin, R. L., & Carnes, C. A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707403 · Cited by 43 · cited 1×
“1 channels are expressed in human ventricle (48) and 4-AP has been shown to prolong APs in a canine ventricular cell model (49).”
BackgroundSevere Accidental Overdose of 4-Aminopyridine Due to a Compounding Pharmacy Error
Schwam, E. (2009) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2009.04.037 · Cited by 41
Compassionate and innovative treatments in children: a proposal for an ethical framework
Brierley, J., & Larcher, V. (2009) · Archives of Disease in Childhood · doi:10.1136/adc.2008.155317 · Cited by 41
Hundallah, K. J., Alenizi, A., Alhashem, A. M., & Tabarki, B. M. (2016) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2016.03.011 · Cited by 40
4-AMINOPYRIDINE TOXICITY WITH UNINTENTIONAL OVERDOSE IN FOUR PATIENTS WITH MULTIPLE SCLEROSIS
Burton, J., Bell, C. M., Walker, S. E., & O'Connor, P. W. (2008) · Neurology · doi:10.1212/01.wnl.0000339380.23073.58 · Cited by 38 · cited 2×
“In previous studies, severe side effects were reported with intoxications through overdoses (for example due to incorrectly formulated medication) (7, 42-44).”
BackgroundExperience in a short-term trial with 4-Aminopyridine in cerebellar ataxia
Giordano, I., Bogdanow, M., Jacobi, H., Jahn, K., Minnerop, M., Schöls, L. J., Synofzik, M., Teufel, J., & Klockgether, T. (2013) · Journal of Neurology · doi:10.1007/s00415-013-7029-5 · Cited by 29
Self-citationNovel clinical manifestations in patients with KCNA2 mutations
Sachdev, M., Gaínza‐Lein, M., Tchapyjnikov, D., Jiang, Y., Loddenkemper, T., & Mikati, M. A. (2017) · Seizure · doi:10.1016/j.seizure.2017.07.018 · Cited by 23
March, B., & Cardi, T. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903443096 · Cited by 22 · cited 1×
“Although 4-AP has not been reported to induce clinically relevant cardiac effects, such as arrhythmias or alterations in ECG morphology in a thorough QT/QTc trial with healthy subjects up to 60 mg/day (46) and in spinal cord injury patients up to 30 mg/day (47), we carefully monitored each increase of 4-AP, since KV1.”
Isoda, W. C., & Segal, J. L. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.2.133.32089 · Cited by 15 · cited 1×
“Although 4-AP has not been reported to induce clinically relevant cardiac effects, such as arrhythmias or alterations in ECG morphology in a thorough QT/QTc trial with healthy subjects up to 60 mg/day (46) and in spinal cord injury patients up to 30 mg/day (47), we carefully monitored each increase of 4-AP, since KV1.”
Dezinamide for partial seizures: Results of an n‐of‐1 design trial
Privitera, M., Treiman, D. M., Pledger, G. W., Sahlroot, J. T., Handforth, A., Linde, M., France, C. R., Cereghino, J. J., McCutchen, C. B., & Wood, J. H. (1994) · Neurology · doi:10.1212/wnl.44.8.1453 · Cited by 14
Dalfampridine (Ampyra) for multiple sclerosis
Belavic, J. M. (2010) · The Nurse Practitioner · doi:10.1097/01.npr.0000389051.00652.80 · Cited by 7
A Massive Overdose of Dalfampridine
Fil, L. J., Sud, P., & Sattler, S. (2015) · Western Journal of Emergency Medicine · doi:10.5811/westjem.2015.8.26127 · Cited by 6 · cited 2×
“In previous studies, severe side effects were reported with intoxications through overdoses (for example due to incorrectly formulated medication) (7, 42-44).”
Personalized treatment in the epilepsies: challenges and opportunities
Balestrini, S., & Sisodiya, S. M. (2018) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2018.1486189 · Cited by 4
Self-citation
Research works printed but not linked: 1
- M. Msall, S. Braun, C. Granger, Use of the functional independence measure for children (WeeFIM): An interdisciplinary training tape. Dev. Med. Child Neurol. 32, 46–50 (1990).
Cited by
Developmental and epileptic encephalopathies: from genetic heterogeneity to phenotypic continuum
Guerrini, R., Conti, V., Mantegazza, M., Balestrini, S., Galanopoulou, A. S., & Benfenati, F. (2023) · Physiological Reviews · doi:10.1152/physrev.00063.2021 · Cited by 196
Developmental and epileptic encephalopathies
Scheffer, I. E., Zuberi, S., Mefford, H. C., Guerrini, R., & McTague, A. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00546-6 · Cited by 158
“The use of 4-aminopyridine, a K v 1 blocker, in patients with GOF variants improved seizures, ataxia, cognition and speech 52 .”
Knowles, J. K., Helbig, I., Metcalf, C. S., Lubbers, L. S., Isom, L. L., Demarest, S., Goldberg, E. M., George, A. L., Lerche, H., Weckhuysen, S., et al. (2022) · Epilepsia · doi:10.1111/epi.17332 · Cited by 166
Self-citationBackwell, L., & Marsh, J. A. (2022) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-111221-103208 · Cited by 122
Current practice in diagnostic genetic testing of the epilepsies
Krey, I., Platzer, K., Esterhuizen, A. I., Berkovic, S. F., Helbig, I., Hildebrand, M. S., Lerche, H., Lowenstein, D. H., Møller, R. S., Poduri, A., et al. (2022) · Epileptic Disorders · doi:10.1684/epd.2022.1448 · Cited by 127
Self-citation
Metadata
- Authors
- Hedrich, U. B. S., Lauxmann, S., Wolff, M., Synofzik, M., Bast, T., Binelli, A., Serratosa, J. M., Martínez-Ulloa, P., Allen, N. M., King, M. D., Gorman, K. M., Zeev, B. B., Tzadok, M., Wong-Kisiel, L., Marjanovic, D., Rubboli, G., Sisodiya, S. M., Lutz, F., Ashraf, H. P., Torge, K., Yan, P., Bosselmann, C., Schwarz, N., Fudali, M., & Lerche, H.
- Affiliations
- Hertie Institute for Clinical Brain Research (DE)
- Vivantes Klinikum (DE)
- German Center for Neurodegenerative Diseases (DE)
- University of Freiburg (DE)
- Hospital Pedro de Elizalde (AR)
- Centre for Biomedical Network Research on Rare Diseases (ES)
- Hospital Universitario Fundación Jiménez Díaz (ES)
- Ollscoil na Gaillimhe – University of Galway (IE)
- University College Dublin (IE)
- Tel Aviv University (IL)
- Divisions of Child Neurology & Division of Epilepsy, Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.
- Danish Epilepsy Center, Filadelfia, 4293 Dianalund, Denmark.
- University of Copenhagen (DK)
- UCL Queen Square Institute of Neurology (GB)
- University of Tübingen (DE)
- Corresponding author
- Hedrich, Ulrike B. S.
- Lauxmann, Stephan
- Lerche, Holger
- ORCID
- Hedrich, Ulrike B. S.
- Lauxmann, Stephan
- Wolff, Markus
- Synofzik, Matthis
- Bast, Thomas
- Binelli, Adrian
- Serratosa, José M.
- Allen, Nicholas M.
- Gorman, Kathleen M.
- Zeev, Bruria Ben
- Tzadok, Michal
- Wong-Kisiel, Lily
- Marjanovic, Dragan
- Rubboli, Guido
- Sisodiya, Sanjay M.
- Lutz, Florian
- Ashraf, Harshad Pannikkaveettil
- Bosselmann, Christian
- Schwarz, Niklas
- Fudali, Monika
- Lerche, Holger
- Venue
- Science Translational Medicine
- Published
- 2021-09
- Volume
- 13
- Issue
- 609
- Pages
- eaaz4957-eaaz4957
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W3196414892
- Cited by
- 87
- References
- 69
- Citations by year
- 2026: 10 · 2025: 24 · 2024: 18 · 2023: 21 · 2022: 11 · 2021: 3
- FWCI
- 4.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- DZNE Pub (submittedVersion)
- Funders
- National Institute for Health and Care Research
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Hereditary Neurological Disorders
- Keywords
- 4-aminopyridine, KCNA2, gain-of-function mutations, encephalopathy, potassium channelopathy, treatment selection
- MeSH terms
- Gain of Function Mutation, Brain Diseases, Epilepsy, Humans, Mutation, 4-Aminopyridine, Kv1.2 Potassium Channel
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.